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ABSTRACT 
Objective: The present study was conducted to evaluate the antidepressant activity of Medhovikas and its activity is compared with that of 
Imipramine and Mentat. The MAO-A and MAO-B levels were estimated by the Biochemical Method.  
Methods: There are several methods available to evaluate the antidepressant activity. In the present study the antidepressant activity is assessed 
using behavioural despair method such as Forced swim test (FST) in mice. Imipramine is used as a positive control in doses of 10mg/kg and 
20mg/kg, Similar activity was also observed with Medhovikas in doses of 200 and 400mg/kg. Biochemical method in rats to estimate the levels of 
MAO-A and MAO-B, the biogenic amine 5-HT is oxidized by MAO to 5-hydrixy indole acetic acid (5-HIAA) as a major metabolite and is excreted in 
urine. Hence the reduction in the urinary 5-HIAA level from normal after treatment with the test compound was taken as a measure of it’s MAO 
inhibitory action. 
Results : The antidepressant activity of 200 and 400mg/kg of Medhovikas was equivalent to that of 10 and 20mg/kg of imipramine respectively. It 
significantly reduced the duration of immobility indicating antidepressant activity. Significant decrease in brain MAO-A and MAO-B levels were 
observed which was determined by the Biochemical method. 
Conclusion: Antidepressant activity was probably shown by inhibiting MAO-A and MAO-B, There are several methods to detect the monoamine 
oxidaise inhibitor activity of substances. These methods are based on biochemical estimation of biogenic amines and /or their pharmacological 
responses. This shows that Medhovikas is a potential antidepressant and the probable mechanism of action is in interest for further investigation. 
Keywords: Antidepressant, Forced swim test, Imipramine,MAO-A & B, Medhovika and Mentat. 
 
INTRODUCTION 
According to world health report, about 450 million people suffer 
from a mental or behavioural disorder (1). Depression is a 
heterogenous disorder that affects a person’s mood, physical health 
and behavioural skills. Patient with major depression have 
symptoms that reflect changes in brain neurotransmitter, 
specifically norepinephrine (NE), Serotonin and Dopamine. An 
estimated 5.8% of men and 9.5% of women experience the 
depressive episodes in their life time. Suicidal tendency remains one 
of the common outcomes of depressive illness being responsible for 
60% of the death (2-5). Patients with depression have decreased 
social, occupational and educational functioning. An accurate 
diagnosis followed by an effective treatment can improve this 
outcome (6). 
The main symptoms of depression are due to functional deficiency in 
the levels of mono aminergic transmitters: Noradrenalline, 5-
hydroxy triptamine (5-HT) and Dopamine in the brain(7). Drugs that 
increase the level of these neurotransmitters in the CNS show 
antidepressant activity (8). The major antidepressant therapies aim 
for an enhancement in the transmitters levels in the neurons and 
thus normalize the neurotransmission(9). Many of the currently 
available antidepressant drugs have proven to be effective but they 
are burdened with some disadvantages such as various adverse 
effects, problematic interactions and relatively low response(10). In 
addition, it is also reported that only two out of three patients 
respond to any given treatment and of these, one would probably 
have responded to placebo alone (11). 
Depression is a common chronic recurrent syndrome, often 
refractive to drug treatment affecting quality of life and overall 
productivity. The one-year prevalence rate is about 5%(12) (Paykel et 
al., 2005) and recurrence rates up to 85% have been reported (13) 
(Lee and Murray, 1988). Although, several classes of antidepressants 
are currently being used, due to clinical limitations and adverse 
effects there is critical interest in development of efficient and safe 
drugs for treatment of depression (Tran et al., 2003). Plant sources 
such as Withania somnifera (Bhattacharya et al., 2000), Bacopa 
monniera (Sairam et al., 2002) and St. John's wort extract (Kasper et 
al., 2006) have been reported to have antidepressant activity and 
can be effective therapeutic alternatives for treatment of depression. 
Depression is commonly accepted to be a disorder due to 
disturbances in neurotransmitters function, particularly serotonin, 
noradrenalin and dopamine (14) (Maes and Meltzer, 1995; Posener et 
al., 1994). Reduction in brain serotonin (Anguelova et al., 2003a,b; 
Drevets, 2001) has been reported to be one of the most important 
etiological factors for genesis of depression and the most widely 
used antidepressants namely serotonin reuptake inhibitors (SSRIs) 
increase extracellular availability of serotonin (Schreiber et al., 
1995). Further, noradrenergic and dopaminergic systems are 
reported to be involved and act in tandem with the serotonergic 
system(15) (Millan et al., 2000; Koch et al., 2002). As medhovikas 
showed significant antidepressant activity in behavioural despair 
method in mice reported by Porsolt et al (1977)(18), the present 
study was conducted to know whether the antidepressant activity is 
due to the possible inhibition of monamine oxidase enzyme. The 
enzyme monamine oxidase enzyme (MAO) is present in several 
tissues. It is concerned with metabolism of biogenic amines such as 
5-hydroxytryptamine (5-HT), noradrenaline etc. Inhibition of MAO 
activity leads to enhanced tissue levels of amines and with a 
reduction in the formation and excretion of their metabolites. There 
are several methods to detect the monoamine oxidaise inhibitor 
activity of substances. These methods are based on biochemical 




Swiss albino mice weighing 25-30gms and Albino rats of either sex 
weighing between 140-210gms were used. They were housed in 
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standard polypropylene cages and maintained under the standard 
conditions: room temperature (253)0 C, humidity 45%-55%, 12/12 
hr light/dark cycle. They were fed with commercially available 
mouse normal pellet diet and water was allowed ad libitum. The 
animals were acclimatized to the laboratory conditions one week 
prior to the behavioral experiments. The animal handling was 
performed according to the Good Laboratory Practice (GLP) 
guidelines. Animals used in this study were treated and cared for in 
accordance with the guidelines recommended 
(Reg.No.1217/A/08/CPCSEA/MRCP/PHD/4) by the Institutional 
Animal Ethics Committee of College..  
Drugs: Medhovikas (Suveda herbals, Tirupati), Bacopa monniera 
(Suveda herbals, Tirupati), Centella asiatica (Suveda herbals, 
Tirupati), Imipramine hydrochloride (Torrent pharmaceuticals 
Ltd.,India), MentatR (Himalaya drug Co., Banglore); 
Chemicals: 1-Nitroso-2-napthol (Loba-chemi, bombay); 2,4-
Dinitrophenyl hydrazine GR (Loba-chemi, co, bombay);5-hydroxy 
indole acetic acid (Sigma chemical company, USA)  
Apparatus: Apparatus consists of a glass beaker (11cm diameter, 
15cm height) containing frech water upto a height of 6 cm 
maintained at a temperature of 22+-10C (Chaturvedi HK et al,1999) 
Grouping and Treatment 
For FST activity-Mice 
The animals were randomly distributes into 11 groups each 
containing 10 animals and marked with unique identification. 
Group I : Control (0.3ml of 2%gum acacia suspension). 
Group II and III: Imipramine, 10mg/kg and 20mg/kg respectively.  
Group IV and V : Medhovikas, 200mg/kg & 400mg/kg respectively.  
Group VI and VII : Mentat, 200mg/kg and 400mg/kg respectively. 
Group VIII and IX: Bacopa monniera(BM), 200mg/kg and 400mg/kg 
respectively. 
Group X and XI : Centella asiatica(CA), 200mg/kg and 400mg/kg 
respectively. 
For MAO activity-Rats 
The animals were randomly divided into seven groups each 
containing five rats. they were marked with unique identifications 
and they were arranged in metabolic cages suitable for the collection 
of urine. 
Rats of group A served as control and were treated orally with 2% 
gum acacia suspension. Rats of groups B and C were treated 
respectively with moclobemide 50mg/kg and 100mg/kg orally 
suspended in 2% gum acacia. Rats of group D, E, F, G were 
administered orally with Medhovikas (MV) 100mg/kg, Mentat 
100mg/kg, BM 100mg/kg, CA 100mg/kg respectively in 2%gum 
acacia suspension. The treatment was given for 3 days in all groups. 
24 hr urine samples were collected daily for 3 days before, during 
and after for 4 days after the treatment. the volume of urine 
collected during 24 hrs was noted and the aliquots of urine sample 
were analysed for 5-HIAA as described below. 
Preparation of standard curve for estimation if 5-HIAA in urine:  
1. 1-Nitroso-2-napthol: 0.1% solution in ethanol. 
2. Nitrous acid reagent: to 5ml of 2N sulphuric acid, 0.2ml of 2.5% 
of sodium nitrate was added. It as always prepared afresh. 
3. Diethyl ether (reagent grade) was washed with dilute solution 
of ferrous sulphate to remove peroxides and later twice with 
water. 
4. 2,4-Dinitrophenyl hydrazine: 0.5%2,4-Dinitrophenyl hydrazine 
in 2N HCl 
5. Phosphate buffer (0.5N) PH>7.0 
Preparation of stock solution of 5-HIAA: A stock solution was 
prepared by dissolving 50 mg of 5-HIAA in 100 ml of distilled water 
in a volumetric flask, which represents 0.5mg/ml of solution. 
Preparation of standard working solutions: From the above stock 
solution further dilutions were made to represent 
50,100,200,400,600 and 800mcg/10ml of the solution. 
METHODS  
Laboratory Models for Assessment of Antidepressant Activity: 
Forced swim test  
The samples were freshly suspended in 2%gum acacia and were 
injected intraperitoneally on the second day before the test session. 
The animals were forced to swim individually, for 15min, on first 
day. This constitutes the ‘pretest’ session. Twenty four hours later, 
30min after the administration of vehicle/test sample, each mouse 
was gently dropped in to the water in the beaker and was left for 6 
minutes. The duration of immobility occurring was recorded. A 
mouse was judged to be immobile when it ceased struggling and 
remained motionless in the water making only those movements 
necessary to keep it’s head above the water. Because little 
immobility is observed during first 2 minutes, the immobility 
observed during the last 4 minutes of 6 minutes test session was 
taken as response time.  
1. Immobility: floating in water without swimming. 
2. Swimming: active movements of extremities and circling in the 
container. 
3. Climbing: active movements of forelimbs on the container wall. 
Monamine Oxidase Inhibitory Activity Of Medhovikas 
In the present work, the MOA inhibitory activity of the Medhovikas 
was studied by biochemical method where the urinary excretion of 
metabolite of 5-HT was determined in 24 hour urine samples of rats 
and it was compared with that of moclobemide, a known MAO 
inhibitor which was used as a reference substance. Simultameously 
MAO inhibitory activity of Mentat, BM, and CA was also studied as it 
was not reported earlier. The procedure adapted is described below. 
Biochemical method in rats 
The biogenic amine 5-HT is oxidized by MAO to 5-hydrixy indole 
acetic acid (5-HIAA) as a major metabolite and is excreted in urine 
(Udenfriend et al., 1955). Hence the reduction in the urinary 5-HIAA 
level from normal after treatment with the test compound was taken 
as a measure of it’s MAO inhibitory action. The method reported by 
Udenfriend et al 1955 was followed in the present study. 
Principle of estimation of 5-HIAA: The 5-HIAA in solutions and urine 
samples was determined by measuring the optical density at 540nm 
on treating it with nitroso napthol reagent followed by nitrous acid 
reagent, after removal of the interfering keto acids by treating with 
2,4dinitrophenyl hydrazine and extracting with chloroform.  
Method: To prepare 10ml of standard solution in a 50 ml glass 
stoppered bottle, 10ml of 2,4dinitrophenyl hydrazine reagent was 
added. after 30min 25ml of chloroform was added, the bottles were 
shaken for 10min and then centrifuged. After phase separation 
organic layer was removed and replaced with a fresh 25ml portion 
of chloroform and the extraction was repeated. after centrifuging, 
15ml of aqueous layer was taken into 50ml stoppered bottle. To this 
8g of sodium chloride and 25ml of ether were added. These bottles 
were shaken for 5min on a shaker and centrifuged. After 
centrifugation and phase separation 20ml ether was taken into 50ml 
glass stoppered bottle containing 4ml of phosphate buffer at ph 7.0. 
It was shaken for 5min, centrifuged and ether was removed by 
aspiration. Later 3ml of buffer layer was taken into 15ml stoppered 
tubes. To this 1.5 ml of nitrosonapthol reagent and 1.5ml of nitrous 
acid reagent were added and mixed well and were kept at 37oc for 
5min. Then 5ml of ethyl acetate were added and after phase 
separation the ethyl acetate layer was aspirated. The above step was 
repeated with another 5ml of ethyl acetate. From the above aqueous 
solution 4ml was transferred into a cuvette and the optical density 
was measured at 540nm against reagent blank. The reagent blank 
for the blank setting of the instrument was prepared by treating 
10ml of distilled water in the same manner.  
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All the results were expressed as mean  Standard error. A 
probability level of p<0.01 was considered as significant. The mice 
brain MAO-A and MAO-B levels of different groups were analysed 
using ANOVA, followed by Dunnett’s ‘t’ test. 
RESULTS 
Effect of Medhovikas on immobility periods in FST 
The response time was recorded for each mouse and mean SEM 
values were calculated for each group and were given in the Table-1. 
All the drugs were found to reduce the response time in a dose 
dependent manner. The effect produced by 200 and 400mg/kg 
doses of Medhovikas,10 and 20mg/kg doses of imipramine, 200 and 
400mg/kg doses of Menat, 200 and 400mg/kg doses of CA were 
statistically significant and compared to control group(P<0.001). 
Biochemical method in rats 
Average values of 3 such determinations are given in Table-2. 
A linear relationship between the amount of 5-HIAA and the optical 
densities was found in the range of 50 to 800 mcg. 
A positive correlation between concentration of 5-HIAA and the 
corresponding optical densities was observed. A plot of the amount 
of the 5-HIAA Vs the corresponding optical densities were shown 
below. The amount of 5-HIAA in the unknown sample was directly 
read from the standard graph.  
Estimation of 5-HIAA in urine: The 5-HIAA levels in urine samples 
were analysed in the same manner as described earlier and the 
amount of 5-HIAA excreted during 24hrs was calculated. 
The 5-HIAA levels in 24hrs urine samples before, during and after 
treatment of rats with test substance are shown in the Table-3. and 
percentage changes of 5-HIAA levels calculated from average of the 
values obtained on the 3 days prior to drug treatment was also 
shown in the Table-4. The significance of Medhovikas, Mentat, 
Moclobemide, BM, CA treatment on urinary 5-HIAA levels compared 
to pre treatment levels was tested by applying unpaired student’s t-
test. All the drugs produced significant change. The percentage off 
change in 5-HIAA levels observed with Medhovikas (100mg/kg) was 
equivalent to that of moclobemide (50mg/kg) indicating that they 
produced similar effect. Also the percentage change of 5-HIAA levels 
observed with CA(100mg/kg) was almost equal to that of 
Moclobemide (100mg/kg) indicating that they produced similar 
effect. 
DISCUSSION 
Animal models like mother-infant separation in monkeys, amine 
depletion by reserpine, learned helplessness etc. are available for 
creating depression and for testing substances for antidepressant 
action. Eventhough none of animal models correspond to inherited 
condition of clinical depression in man, the animal models were used 
for screening substances for antidepressant activity as some of the 
underlying biochemical mechanisms were common to clinical 
depression and experimentally produced depression in animals. 
These models with their mechanisms were reviewed by Porsolt 
(1985). 
In our studies, Medhovikas was tested for antidepressant activity in 
mice following the method reported by Porsolt(1977) since it can be 
used as a regular screening test in laboratory conditions. 
Imipramine which is used as a positive control in doses of 10 and 
20mg/kg, significantly reduced the duration of immobility indicating 
antidepressant activity. Similar activity was also observed with 
Medhovikas in doses of 200 and 400mg/kg bodyweight. 
Mentat was found to have significant antidepressant effect, following 
subchronic administration, which was quantitatively compared to 
that induced by the standard imipramine (Bhattacharya, 1994). In 
present study, the activity of single dose administration of Mentat in 
doses of 200 and 400mg/kg (i.p) bodyweight was found to be less 
effective than 200 and 400mg/kg doses of Medhovikas respectively. 
In low dose (200mg/kg), CA was found to be more effective than BM 
and in high dose (400mg/kg), BM was found to be more effective 
than CA. 
The antidepressant activity of 200 and 400mg/kg of Medhovikas was 
equivalent to that of 10mg/kg and 20mg/kg of imipramine 
respectively. This shows that Medhovikas is a potential 
antidepressant. 
The enzyme MAO is present in several tissues like liver, brain, 
platelets and enterochromaffin cells. It participates in the oxidative 
deamination of the several endogenous amines like adrenaline, 
noradrenaline, 5-HT etc. Several substances of diverse chemical 
structures are reported it inhibit this activity. compounds reported 
to have MAO inhibitory activity are iproniazid, tranyl cypromine and 
phenelezine of the two major molecular species of MAO, type A is 
selectively inhibited by moclobemide and prefers serotonin as a 
substrate. Substances that inhibit MAO activity reduce rate of 
formation of metabolites of monoamines or completely block their 
metabolism by deamination pathway with consequent reduction in 
the total amount of metabolite formation. This fact is made use of to 
provide evidence for MAO inhibitory activity of Medhovikas. 
Table-1 :Effect Of Medhovikas on Immobility period in Forced 


















































































































Statistical analysis of data was carried out by one-way ANOVA 
followed by Dunnett’s t-test.*P<0.05,**P<0.01 and ***P<0.001 as 
compared to Control; FST-Forced Swim Test. 
Table 2: Biochemical Method in rats 
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Table 3: Daily urinary 5-HIAA in rats 
 
Days 
Daily Urinary 5-HIAA ((µg) in rats treated with 





























































Statistical analysis of data was carried out by one-way ANOVA followed by Dunnett’s t-test.*P<0.05,**P<0.01 and ***P<0.001 as compared to 
Control. 
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